In endometrial cancer patients, higher HNRNPC, YTHDC2, WTAP, VIRMA, IGF2BP3, and HNRNPA2B1 expression is closely associated with worse outcomes and advanced stage (Zhao et al., 2021). Here, YTHDC2 is linked to endometrial cancer.